Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination Patients With Thalassemic and Falcemic Syndromes (HEMOGLOB-VAX)

  • STATUS
    Recruiting
  • End date
    Dec 31, 2030
  • participants needed
    1000
  • sponsor
    Società Italiana Talassemie ed Emoglobinopatie
Updated on 24 March 2022
Accepts healthy volunteers

Summary

There is an urgent need to rapidly evaluate anti-Covid 19 vaccination treatments, in terms of immune response (humoral and cell-mediated) together with the verification of the effectiveness of the vaccine in preventing SARS-CoV-2 infection in thalassemic subjects.

It is also necessary to increase scientific knowledge in order to improve clinical practice to have presence responses and maintenance extent of the response to vaccinations against encapsulated bacteria carried out previously.

The objectives of the main study are:

  1. Evaluate the appearance, extent, and duration of humoral response (antibodies) to the anti-SARS-CoV-2 vaccine;
  2. Assess the incidence of positive cases after vaccination.

The objective of the first sub-study is:

  • Evaluate the appearance, extent, and duration of cellular response (T lymphocytes and B lymphocytes) to the anti-SARS-CoV-2 vaccine based on age groups and the presence/absence of hypo/asplenia.

The objective of the second sub-study is:

  • Evaluate the presence and extent of the response to previous vaccinations to encapsulated bacteria.

Description

This is a non-profit multicenter observational study, coordinated by the Department of OncoHematology,Cell Therapy, Gene Therapies and Hematopoietic Transplantation of the Bambino Gesù Children'sHospital, IRCCS which provides for the collectionof clinical data of patients with an established diagnosis of TDT and SCD after the administration of the anti-SARS-CoV-2vaccine.

As this is a prospective study for medium-term assessments, it is expected to last no less than 18 months. The duration of the prospective observation will start from April 2021 for the duration of 12 months.

Setting

The following will be enrolled:

  • for the main study patients diagnosed with TDT and SCD even if they have previously contracted SARS-CoV-2 infection;
  • for the first substudy, patients with TDT and SCD diagnosis will be enrolled, divided by presence/absence of hypo/asplenia;
  • for the second substudy, patients diagnosed with TDT and hypo/asplenic SCD will be enrolled.

The Scientific Committee of the project discussed and approved a dataset that will be collected by local centers, the pseudo-anonymized data of patients collected in a special e-CRF.

The participating centers are:

  • Rome, Brindisi, Cagliari, Genoa, Ferrara, Milan, Naples, Palermo Turin, Verona.

The Italian Society of Thalassemia and Hemoglobinopathies (SITE) in its role as a scientific society of reference for the pathology will act as Promoter of the experimentation and the ForAnemia Foundation, a non-profit organization, is also identified as a funder of the present study.

The project will be developed through the creation and validation of a data collection card in which the clinical data relating to all patients with the characteristics of inclusion in the participating centers will be entered.

The data to be entered include characteristics of the patient, in addition to epidemiological data (sex, age) and clinical data (diagnosis), pre-existing comorbidities, indication of iron overload, drugs administered. Data analysis will be primarily descriptive.

It is accepted in advance that this protocol may require repeated modifications to conform to the evolution of knowledge about the pandemic, the complication rate and the therapeutic scenario. A high degree of adaptation is therefore expected, which will be rigorously discussed with the independent data monitoring committee that will be appointed immediately after the approval of the protocol.

Study population Patients with TDT and SCD. Inclusion criteria

Main study and first substudy:

  • Patients with advancedTDT and SCD diagnosis, age > 18 years
  • signature of informed consent.

Second substudy:

  • Splenectomized patients withTDT and SCD diagnosed, age > 18 years
  • signature of informed consent. Exclusion criteria No signature informed consent. Results of the Study

The following variables will be measured:

  • anti_N Antibody Value
  • Anti-RBD values
  • memory andi-trimeric Spike IgG in total memory (% of total IgG memory)
  • Immunity value T (IFN-g) Variables Samples for the analysis of humoral and cell-mediated response will be collected before vaccination (T0), at booster (T1), between 14 and 21 days after recall (T2) and after 12, 24 and 52 weeks after vaccination.

Sampling before vaccination (T0) can be collected up to 5 days before vaccination. Sampling prior to administration of the booster (T1) may be collected up to 5 days in advance.

Withdrawals at weeks 12, 24, 52 will be performed with a tolerance of 10 days.

  • The analysis of the presence of specific antibodies (IgG) to N and S viral antigens will be carried out by CMIA method. The analysis of both antibodies will allow to evaluate the response to the vaccine (anti-S antibodies) and a possible natural exposure/infection (anti-N antibodies). In patients who present anti-S antibodies, neutralizing titiness measurement will be performed.

Details
Condition SARS-CoV-2 Infection, Thalasemmie, SCD
Clinical Study IdentifierNCT05157256
SponsorSocietà Italiana Talassemie ed Emoglobinopatie
Last Modified on24 March 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Inclusion criteria
Main study and first substudy
Patients with advancedTDT and SCD diagnosis, age > 18 years
signature of informed consent
Second substudy
Splenectomized patients withTDT and SCD diagnosed, age > 18 years
signature of informed consent

Exclusion Criteria

No signature informed consent
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note